About Us

Procaps Group, S.A. (“Procaps”)  is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and nearly 5,000 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions.

ESG Report 2022

Our Sustainable Way: Driving Innovation, shaping a Healthier Future

View Report
ESG Report

Recent News

Procaps Group Receives Delisting Notice From Nasdaq

February 3, 2025

MIAMI and BARRANQUILLA, Colombia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC

View More

Pharmaceutical Group dedicated to delivering health and nutrition

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5.000 people across 13 countries

We employ over 5.000 people across 13 countries
 

Our products reach 50+ markets

Our products reach 
50+ markets